• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Therapeutic, clinical and histological factors related to the survival of patients with advanced ovarian carcinoma.

作者信息

Kauppila A, Kivinen S, Mäkilä U M, Järvinen P A

出版信息

Ann Chir Gynaecol. 1981;70(3):91-5.

PMID:7325582
Abstract

Retrospective evaluation of 137 patients with advanced ovarian carcinoma was attempted 4-12 years after therapy. The operation was radical or almost radical in 56 cases (40.8%). Postoperative treatment consisted of single-drug (N = 53) or multi-drug cytotoxic chemotherapy (N = 53) and irradiation alone (N = 8) or together with cytotoxic chemotherapy (N = 53). Postoperative therapy of any kind was impossible in 23 cases. Nine patients were alive 5 years after therapy. Eight of them had had a clinical stage III (survival rate 7.7%) and one clinical stage IV malignancy (survival rate 3.0%). The extent of the operation was of major importance, 8 out of 9 survivors having undergone a radical operation, which also prolonged the life of the non-survivors. Single drug chemotherapy and combination chemotherapy yielded similar results, 4 and 5 survivors, and 21.1 and 19.6 months as the mean length of survival respectively. None of the patients on postoperative radiotherapy survived. Their mean survival period was 16.6 months. Radiotherapy as an additional measure did not produce any benefit. The prognosis was most favourable for patients with serous cystadenocarcinoma. A poor prognosis was typical of nulliparous women, suggesting that hormones may contribute to the clinical behaviour of this illness.

摘要

相似文献

1
Therapeutic, clinical and histological factors related to the survival of patients with advanced ovarian carcinoma.
Ann Chir Gynaecol. 1981;70(3):91-5.
2
Results of treatment of primary ovarian carcinoma.
Ann Chir Gynaecol. 1982;71(3):156-60.
3
[The therapeutic value of second-look laparotomy in advanced ovarian carcinoma].[二次剖腹探查术在晚期卵巢癌中的治疗价值]
Zentralbl Gynakol. 1988;110(22):1443-8.
4
[Postoperative radiotherapy of epithelial ovarian cancers].[上皮性卵巢癌的术后放疗]
Geburtshilfe Frauenheilkd. 1985 Dec;45(12):848-52. doi: 10.1055/s-2008-1036488.
5
Factors influencing ovarian cancer survival after chemotherapy.影响化疗后卵巢癌生存率的因素。
Obstet Gynecol. 1974 Oct;44(4):564-70.
6
The current therapeutic approaches to advanced ovarian cancer.晚期卵巢癌的当前治疗方法。
Nihon Sanka Fujinka Gakkai Zasshi. 1990 Dec;42(12):1691-6.
7
Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.美法仑与顺铂联合化疗作为晚期卵巢癌初始治疗的随机试验:初步及长期结果——东部肿瘤协作组E2878研究
Cancer. 1996 Feb 15;77(4):733-42.
8
[Postoperative radiotherapy of malignant ovarian tumors. I: Results following telecobalt grid irradiation].恶性卵巢肿瘤的术后放疗。I:钴远距离格栅照射后的结果
Radiobiol Radiother (Berl). 1982;23(5):497-502.
9
[Our experience in treating endometrioid ovarian carcinoma].[我们治疗子宫内膜样卵巢癌的经验]
Akush Ginekol (Sofiia). 1991;30(1):29-32.
10
The management of ovarian carcinoma--a review of 420 cases.
Scott Med J. 1970 Jul;15(7):250-6. doi: 10.1177/003693307001500704.